Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 6/20 | 0.50 |
| ▸ | CCR1 | P32246 | 4/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CAPN9 | O14815 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6985559 | 0.91 | CAPN1 (0.58) | CAPN1CCR1GAACAPN9CTSB | |
| SCHEMBL6981138 | 0.90 | CAPN1 (0.57) | CAPN1GAACAPN9CTSBMAPK1 | |
| SCHEMBL6985150 | 0.89 | NPSR1 (0.50) | CAPN1CCR1GAAMAPK1KDM4E | |
| SCHEMBL6984518 | 0.88 | L3MBTL1 (0.49) | CAPN1GAACAPN9CTSBMAPK1 | |
| SCHEMBL6985309 | 0.85 | CAPN1 (0.54) | CAPN1CCR1GAACAPN9CTSB | |
| SCHEMBL10859075 | 0.81 | CAPN1 (0.56) | CAPN1CCR1CAPN9CTSBMAPK1 | |
| SCHEMBL10859034 | 0.81 | CAPN1 (0.56) | CAPN1CCR1CAPN9CTSBMAPK1 | |
| SCHEMBL8209979 | 0.81 | KDM4E (0.54) | CAPN1GAACAPN9CTSBMAPK1 | |
| SCHEMBL10858129 | 0.81 | KDM4E (0.54) | CAPN1GAACAPN9CTSBMAPK1 | |
| SCHEMBL8205854 | 0.81 | KDM4E (0.54) | CAPN1GAACAPN9CTSBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6551999-B1 | For therapy and prophylaxis of angiogenesis associated with wound healing, inflammation, growth of tumor and the like; angiogenesis as seen in diabetic retinopathy, prematurity retinopathy, retinal venous occlusion, metastasis of tumors | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2003-04-22 | — | — | US | disclosed |
| EP-0771565-B1 | Angiogenesis inhibitor | SENJU PHARMA CO (JP) | 2003-01-02 | — | — | EP | disclosed |
| US-6214800-B1 | ANGIOGENESIS INHIBITORS | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2001-04-10 | — | — | US | disclosed |
| US-6057290-A | ADMINISTERING A CYSTEINE PROTEASE INHIBITOR TO A PATIENT FOR INHIBITING ANGIOGENESIS | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2000-05-02 | — | — | US | disclosed |
| EP-0928786-A1 | Angiogenesis inhibitor | Senju Pharmaceutical Co., Ltd. (JP) | 1999-07-14 | — | — | EP | disclosed |
| EP-0927716-A1 | Angiogenesis inhibitor | Senju Pharmaceutical Co., Ltd. (JP) | 1999-07-07 | — | — | EP | disclosed |
| EP-0838460-A1 | PIPERAZINE DERIVATIVES AND USE OF THE SAME | Senju Pharmaceutical Co., Ltd. (JP) | 1998-04-29 | — | — | EP | disclosed |
| EP-0771565-A2 | Angiogenesis inhibitor | Senju Pharmaceutical Co., Ltd. (JP) | 1997-05-07 | — | — | EP | disclosed |